Autoimmune cardiolipin-binding antibodies in oral anticoagulant patients

T Exner1, J Koutts

  • 1Hematology Dept, Westmead Hospital, NSW, Australia.

Australian and New Zealand Journal of Medicine
|August 1, 1988
PubMed

Insights

Elevated anticardiolipin antibody (ACA) levels were found in 14% of patients on warfarin therapy. Raised ACA may indicate an acquired prothrombotic state, particularly in younger patients with thromboses.

Area of Science:

  • Immunology
  • Hematology

Background:

  • Oral anticoagulant therapy, such as warfarin, is common for managing thrombotic conditions.
  • Anticardiolipin antibodies (ACA) are associated with thrombophilia, but their prevalence in patients on anticoagulation requires further investigation.

Purpose of the Study:

  • To determine the prevalence and significance of elevated anticardiolipin antibody (ACA) levels in patients undergoing routine oral anticoagulant therapy.
  • To explore potential associations between raised ACA and patient demographics, clinical indications for anticoagulation, and autoimmune markers.

Main Methods:

  • A well-standardized enzyme-linked immunosorbent assay (ELISA) was used to assess ACA levels in 140 patients on warfarin.
  • Patients were categorized based on their treatment indication (thrombotic episodes vs. heart valve replacement).
  • Additional autoimmune markers, including antinuclear antibodies (ANA) and lupus anticoagulant, were evaluated in a subset of patients.

Main Results:

  • 14% of patients on warfarin therapy exhibited elevated ACA levels ( > 4 SD above normal).
  • A higher incidence of raised ACA was observed in patients treated for thrombotic episodes (19%) compared to those with heart valve replacements (11%).
  • The highest ACA titers were noted in younger patients with thromboses on short-term anticoagulation; autoimmune etiology was suggested in a minority.

Conclusions:

  • Elevated ACA is a significant finding in patients on oral anticoagulant therapy.
  • Raised ACA may serve as a marker for an acquired prothrombotic state, warranting further clinical consideration.
  • ACA did not appear to negatively impact patient conditions during anticoagulant therapy.

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...